medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 4

<< Back Next >>

Ann Hepatol 2005; 4 (4)

Performance of the serologic and molecular screening of blood donations for the hepatitis B and C viruses in a Mexican Transfusion Center

Chiquete E, Sánchez LV, Becerral G, Quintero Á, Maldonado M, Panduro A

Language: English
References: 15
Page: 275-278
PDF size: 50.60 Kb.


Text Extraction

Nucleic acid-amplification testing (NAT) is not routinely practiced in blood banks from most low-income countries. We did an exploratory comparison of the performance of the standard immunoassay-based screening tests for the hepatitis B (HBV) and C (HCV) viruses with that of NAT, in blood donors. From January 1999 to March 2005, 94,806 blood donors were screened for anti-HCV antibodies and for hepatitis B surface antigen (HBsAg). Also, an exploratory period of molecular screening was carried out on 100 consecutive blood donors to detect HBV DNA and HCV RNA by home-made PCR techniques without sera pooling. In the 75-month period of serologic screening, HBsAg was detected in 219 donors (0.23%; 95% CI, 0.20–0.26%) and anti-HCV antibodies in 922 (0.97%; 95% CI, 0.90–1.03%). The annual trend for HBsAg prevalence had a decreasing pattern over the years (p ‹ 0.001), whereas that for anti-HCV did not (p = 0.19). In the molecular screening cohort, HBV DNA was detected in one donor (1%; 95% CI, 0–6%) and HCV RNA in another (1%; 95% CI, 0–6%). All these 100 donors tested negative to HBsAg and anti-HCV. Thus, the prevalence of positive results for HBV and HCV did not differ if considering immunoassays or NAT; nevertheless, these methods did not coincide in detecting HBV or HCV in the molecular screening cohort. In conclusion, NAT can detect cases of HBV and HCV infections that standard immunoassay techniques can not, even in a highly selected population at low risk, like blood donors. Large-scale studies are warranted for NAT to be considered as a systematic method for screening of HBV and HCV in Mexican blood banks.


REFERENCES

  1. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-33.

  2. Rivera-López MR, Zavala-Méndez C, Arenas-Esqueda A. Prevalence for seropositivity for HIV, hepatitis B and hepatitis C in blood donors [in Spanish]. Gac Med Mex 2004; 140: 657-660.

  3. SSA. Mexican Official Norm on the use of human blood and its components with therapeutic objectives (NOM-003-SSA2-1993); Mexico, 1993. Available at http://www.salud.gob.mx/. Accessed July 25 2005.

  4. Méndez-Sánchez N, Villa AR, Chávez-Tapia NC, Ponciano-Rodríguez G, Almeda-Valdés P, González D, et al. Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data. Ann Hepatol 2005; 4: 52-55.

  5. Sookoian S, Castaño G. Evaluation of a third generation anti-HCV assay in predicting viremia in patients with positive HCV antibodies. Ann Hepatol 2002; 4: 179-182.

  6. Dal Molin G, Tiribelli C, Campello C. A rational use of laboratory tests in the diagnosis and management of hepatitis C virus infection. Ann Hepatol 2003; 2: 76-83.

  7. Chiquete E, Sánchez LV, Maldonado M, Quezada D, Panduro A. Prediction of the hepatitis C viremia using immunoassay data and clinical expertise. Ann Hepatol 2005; 4: 107-114.

  8. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M. Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 2004; 50: 159-162.

  9. Rivas-Estilla AM, Sánchez LV, Matsui O, Campollo O, Armendariz-Borunda J, Segura-Ortega JE, Panduro A. Identification of hepatitis C virus (HCV) genotypes in infected patients from the west of Mexico. Hepatology Research 1998; 12: 121-130.

  10. Sánchez LV, Maldonado M, Bastidas-Ramírez BE, Norder H, Panduro A. Genotypes and S-gene variability of Mexican hepatitis B virus strains. J Med Virol 2002; 68: 22-34.

  11. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567.

  12. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351: 760-768.

  13. Koerner K, Cardoso M, Dengler T, Kerowgan M, Kubanek B. Estimated risk of transmission of hepatitis C virus by blood transfusion. Vox Sang 1998; 74: 213-216.

  14. Flanagan P, Snape T. Nucleic acid technology (NAT) testing and the transfusion service: a rationale for the implementation of minipool testing. Transfusion Med 1998; 8: 9-13.

  15. Romano L, Velati C, Baruffi L, Fomiatti L, Colucci G, Zanetti AR, et al. Multicenter evaluation of a semiautomated, standardized assay for detection of hepatitis B virus DNA in blood donations. J Clin Microbiol 2005; 43: 2991-2993.




2020     |     www.medigraphic.com